罗替戈汀杂质19 | 835654-68-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 罗替戈汀杂质19
• 英文名称: O-Acetylrotigotine
• 英文别名: [(6S)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-yl] acetate
• CAS: 835654-68-7
• 化学式: C₂₁H₂₇NO₂S
• 分子量: 357.5
• InChiKey: DSYJRJFDFYEVFD-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  57.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• ROTIGOTINE BEHENATE, AND MANUFACTURING METHOD AND APPLICATION THEREOF
  申请人：Shandong Luye Pharmaceutical Co., Ltd.

  公开号：US20190330177A1

  公开（公告）日：2019-10-31

  The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.

  本公开涉及罗蒂吡嗪癸酸酯，其制备方法以及用于治疗与多巴胺受体相关的疾病的用途。罗蒂吡嗪癸酸酯的结构如下图所示，能够减少血液药物浓度的波动，提高药物在体内的生物利用度，并实现罗蒂吡嗪的平稳和延长释放。
• [EN] PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE)<br/>[FR] PROCÉDÉ DE SYNTHÈSE DU (6S)-(-)-5,6,7,8-TÉTRAHYDRO-6-[PROPYL-(2-THIÉNYL)ÉTHYL]AMINO-1- NAPHTOL(ROTIGOTINE)
  申请人：INTERQUIM SA

  公开号：WO2010066755A1

  公开（公告）日：2010-06-17

  The present invention describes a novel process for the preparation of (6S)-(-)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine) comprising: (a) acetylating (S)-(-)-5-hydroxy-N-n-propyl-2-aminotetraline to afford the acetate; (b) reacting this acetate, (-)-5-acetoxy- N-n-propyl-2-aminotetraline, with 2-(2-thienyl)ethanol 2- nitrobenzenesulfonate; (d) hydrolyzing (6S)-(-)-1-acetoxy-5, 6,7,8- tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthalene to afford (6S)-(- )-5, 6, 7, 8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine) and (d) purifying rotigotine either by the acetylation reaction and subsequent hydrolysis of the formed acetate or by salification of rotigotine through hydrochloride or hydrobromide formation and subsequent base release. Rotigotine is a dopamine agonist and is indicated for the treatment of Parkinson's disease.

  本发明描述了一种新型制备(6S)-(-)-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘酚（洛地静）的方法，包括：(a) 乙酰化(S)-(-)-5-羟基-N-丙基-2-氨基四氢萘制得醋酸盐；(b) 用2-(2-噻吩基)乙醇2-硝基苯磺酸盐反应此醋酸盐，(-)-5-乙酰氧基-N-丙基-2-氨基四氢萘；(d) 水解(6S)-(-)-1-乙酰氧基-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘烯制得(6S)-(-)-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘酚（洛地静），(d) 通过醋酸化反应和随后的水解制备洛地静，或通过盐酸或溴化氢盐的形成和随后的碱释放来盐化洛地静。洛地静是一种多巴胺激动剂，适用于帕金森病的治疗。
• PROCESS FOR THE PREPARATION OF (6S)-(-)-5,6,7,8-TETRAHYDRO-6-[PROPYL-(2-THIENYL)ETHYL]AMINO-1-NAPHTHOL (ROTIGOTINE)
  申请人：Pomares Marta

  公开号：US20110306776A1

  公开（公告）日：2011-12-15

  The present invention describes a novel process for the preparation of (6S)-(−)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine) comprising: (a) acetylating (S)-(−)-5-hydroxy-N-n-propyl-2-aminotetraline to afford the acetate; (b) reacting this acetate, (−)-5-acetoxy-N-n-propyl-2-aminotetraline, with 2-(2-thienyl)ethanol 2-nitrobenzenesul-fonate; (d) hydrolyzing (6S)-(−)-1-acetoxy-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthalene to afford (6S)-(−)-5,6,7,8-tetrahydro-6-[propyl-(2-thienypethyl]amino-1-naphthol (Rotigotine) and (d) purifying rotigotine either by the acetylation reaction and subsequent hydrolysis of the formed acetate or by salification of rotigotine through hydrochloride or hydrobromide formation and subsequent base release. Rotigotine is a dopamine agonist and is indicated for the treatment of Parkinson's disease.

  本发明描述了一种制备(6S)-(-)-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘酚（罗地克汀）的新工艺，包括：(a) 乙酰化(S)-(-)-5-羟基-N-丙基-2-氨基四氢萘以得到乙酸酯；(b) 将这种乙酸酯，(-)-5-乙酰氧基-N-丙基-2-氨基四氢萘与2-(2-噻吩基)乙醇2-硝基苯磺酸盐反应；(c) 加水解(6S)-(-)-1-乙酰氧基-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘烷以得到(6S)-(-)-5,6,7,8-四氢-6-[丙基-(2-噻吩基)乙基]氨基-1-萘酚（罗地克汀）；(d) 通过乙酰化反应和随后的乙酸酯水解或通过盐酸或溴化氢的形式制得罗地克汀的盐酸盐或溴化物盐并随后释放碱来纯化罗地克汀。罗地克汀是一种多巴胺激动剂，适用于帕金森病的治疗。
• Rotigotine behenate, and manufacturing method and application thereof
  申请人：Shandong Luye Pharmaceutical Co., Ltd.

  公开号：US10669249B2

  公开（公告）日：2020-06-02

  The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.

  本公开涉及山嵛酸罗替戈汀、山嵛酸罗替戈汀的制备方法以及山嵛酸罗替戈汀用于治疗多巴胺受体相关疾病的用途。 山嵛酸罗替戈汀的结构如下图所示，它能够减少血液中药物浓度的波动，提高药物在体内的生物利用度，并实现罗替戈汀的平稳和延长释放。
• US8513438B2
  申请人：——

  公开号：US8513438B2

  公开（公告）日：2013-08-20